缺血/缺氧对心脏胰岛素样生长因子2受体表达调控的实验研究
|
摘要
尽管心血管疾病的治疗方法现已取得了巨大的进展,但是各种心脏疾病导致的心力衰竭在全球仍然具有很高的发病率和死亡率。心力衰竭是一种由多因素引起的疾病,内在的分子机制还不是很清楚,但很可能与潜在的基因和蛋白质表达改变有关。本实验室已经证明胰岛素样生长因子2受体(insulin-like growth factor 2 receptor, IGF-2R)在心衰患者心脏组织的表达显著提高,提示IGF-2R可能在心力衰竭的发生中起重要的作用。本实验检测了IGF-2R在大鼠心肌梗死不同时间点后的动态变化规律,并在体外以缺氧无血清模拟心肌缺血缺氧环境,研究IGF-2R在心肌细胞缺氧无血清时表达的变化以及其与细胞凋亡的关系,为阐明IGF-2R在心肌梗死后心力衰竭发生发展过程中的作用奠定基础。
本论文主要包括以下研究内容：
1雄性SD大鼠180只随机分为两组：心肌梗死模型组和假手术对照组。通过结扎大鼠左冠状动脉前降支制作大鼠心梗模型,梗死后1天、3天、7天、2周、4周和8周取大鼠左心室组织,采用酶联免疫吸附法(enzyme-linked immunosorbent assay, ELISA)检测大鼠心肌梗死区IGF-2R的表达变化规律。结果表明,大鼠心肌梗死后1天、3天IGF-2R表达下降,随后逐渐恢复至正常。
2体外模拟心肌缺血缺氧环境,观察IGF-2R在心肌细胞缺氧无血清时表达的变化。离体培养SD乳鼠心肌细胞,缺氧无血清处理不同时间点后收获细胞,应用反转录聚合酶链式反应(RT-PCR)和实时定量RT-PCR(real time RT-PCR)测定IGF-2R mRNA水平的表达变化,并进一步应用ELISA方法检测IGF-2R在蛋白水平的改变。与对照组相比,IGF-2R mRNA在缺氧无血清处理12h和24h后表达显著增高,缺氧无血清24h后IGF-2R蛋白表达也升高。
3采用脂质体介导siRNA转染心肌细胞抑制IGF-2R mRNA的表达后,采用流式细胞仪检测IGF-2R对缺氧无血清引起的心肌细胞凋亡的影响。结果表明,阻断IGF-2R mRNA的表达对缺氧无血清所引起的心肌细胞凋亡影响不明显。
Despite considerable advances in the treatment of cardiovascular disease, it remains the leading cause of mortality and morbility in the world. Underlying molecular causes of cardiac dysfunction in most heart diseases are still largely unknown but are expected to result from causal alterations in gene and protein expression. We had already found IGF-2R was highly expressed in the tissues samples from heart failure patients compaired with non-failing hearts. In this article we studied changes of expression of IGF-2R during ventricular remodeling following myocardial infarction. In addition, we studied weather IGF-2R played important roles in the process of ischemia induced apoptosis. All of these studies will contribute to the new strategies of treatment of heart falure.
Main contents of this study including:
1 Myocardial infarction was created in SD rats by ligation of the left anterior descending coronary artery. The rats were randomly divided into 2 groups:sham group and myocardial infarction (MI) group. Animals were sacrificed at 1day,3day,7days, 2weeks,4weeks,8weeks after operation and the left ventricular tissues were isolated for determination of IGF-2R by enzyme-linked immunosorbent assay (ELISA). Compaired with the sham group, IGF-2R protein was downregulated 1 and 3day after MI, and then returned to normal levels.
2 Cultured neonatal rat cardiomyocytes were randomly divided into control group and hypoxia and serum deprivation (H/SD) group. Expression of IGF-2R mRNA was measured by RT-PCR and real time RT-PCR. Level of IGF-2R protein was measured by ELISA.Compared with control group, the expression of IGF-2R mRNA increased significantly (P<0.01) in cardiomyocytes cultured in H/SD condition for 12h and 24h, and IGF-2R protein was upregulated in cardiomyocytes cultured in H/SD condition for 24h(P<0.05). H/SD could induce IGF-2R expression, and IGF-2R may involve in the mechanism of cardiomyocyte damage induced by ischemia.
3 Cultured neonatal rat cardiomyocytes were randomly divided into control group, H/SD group, scramble siRNA group and IGF-2R siRNA group.Percentage of apoptotic cells measured by flow cytometry.The results demonstrated that H/SD induced apoptosis of cardiomyocytes, but we did not found that down-regulation of IGF-2R mRNA reduced apotosis in neonatal rat cardiomyocytes cultured in H/SD condition.
本论文主要包括以下研究内容：
1雄性SD大鼠180只随机分为两组：心肌梗死模型组和假手术对照组。通过结扎大鼠左冠状动脉前降支制作大鼠心梗模型,梗死后1天、3天、7天、2周、4周和8周取大鼠左心室组织,采用酶联免疫吸附法(enzyme-linked immunosorbent assay, ELISA)检测大鼠心肌梗死区IGF-2R的表达变化规律。结果表明,大鼠心肌梗死后1天、3天IGF-2R表达下降,随后逐渐恢复至正常。
2体外模拟心肌缺血缺氧环境,观察IGF-2R在心肌细胞缺氧无血清时表达的变化。离体培养SD乳鼠心肌细胞,缺氧无血清处理不同时间点后收获细胞,应用反转录聚合酶链式反应(RT-PCR)和实时定量RT-PCR(real time RT-PCR)测定IGF-2R mRNA水平的表达变化,并进一步应用ELISA方法检测IGF-2R在蛋白水平的改变。与对照组相比,IGF-2R mRNA在缺氧无血清处理12h和24h后表达显著增高,缺氧无血清24h后IGF-2R蛋白表达也升高。
3采用脂质体介导siRNA转染心肌细胞抑制IGF-2R mRNA的表达后,采用流式细胞仪检测IGF-2R对缺氧无血清引起的心肌细胞凋亡的影响。结果表明,阻断IGF-2R mRNA的表达对缺氧无血清所引起的心肌细胞凋亡影响不明显。
Despite considerable advances in the treatment of cardiovascular disease, it remains the leading cause of mortality and morbility in the world. Underlying molecular causes of cardiac dysfunction in most heart diseases are still largely unknown but are expected to result from causal alterations in gene and protein expression. We had already found IGF-2R was highly expressed in the tissues samples from heart failure patients compaired with non-failing hearts. In this article we studied changes of expression of IGF-2R during ventricular remodeling following myocardial infarction. In addition, we studied weather IGF-2R played important roles in the process of ischemia induced apoptosis. All of these studies will contribute to the new strategies of treatment of heart falure.
Main contents of this study including:
1 Myocardial infarction was created in SD rats by ligation of the left anterior descending coronary artery. The rats were randomly divided into 2 groups:sham group and myocardial infarction (MI) group. Animals were sacrificed at 1day,3day,7days, 2weeks,4weeks,8weeks after operation and the left ventricular tissues were isolated for determination of IGF-2R by enzyme-linked immunosorbent assay (ELISA). Compaired with the sham group, IGF-2R protein was downregulated 1 and 3day after MI, and then returned to normal levels.
2 Cultured neonatal rat cardiomyocytes were randomly divided into control group and hypoxia and serum deprivation (H/SD) group. Expression of IGF-2R mRNA was measured by RT-PCR and real time RT-PCR. Level of IGF-2R protein was measured by ELISA.Compared with control group, the expression of IGF-2R mRNA increased significantly (P<0.01) in cardiomyocytes cultured in H/SD condition for 12h and 24h, and IGF-2R protein was upregulated in cardiomyocytes cultured in H/SD condition for 24h(P<0.05). H/SD could induce IGF-2R expression, and IGF-2R may involve in the mechanism of cardiomyocyte damage induced by ischemia.
3 Cultured neonatal rat cardiomyocytes were randomly divided into control group, H/SD group, scramble siRNA group and IGF-2R siRNA group.Percentage of apoptotic cells measured by flow cytometry.The results demonstrated that H/SD induced apoptosis of cardiomyocytes, but we did not found that down-regulation of IGF-2R mRNA reduced apotosis in neonatal rat cardiomyocytes cultured in H/SD condition.
引文
[1]Pearson H. The heart of the matter. Nat Med.2004,10(5):445-446.
[2]Gibbons GH, Liew CC, Goodarzi MO, Rotter JI, Hsueh WA, Siragy HM, Pratt R, Dzau VJ. Genetic Markers:Progress and Potential for Cardiovascular Disease. Circulation.2004,109[suppl IV]:47-58.
[3]McGregor E, Dunn MJ. proteomics of the heart:unraveling disease. Circ Res.2006, 98(3): 309-321
[4]戴闺柱.慢性心力衰竭治疗的现代概念,[J]中华心血管病杂志。2000,28(1):75-78.
[5]Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rational for preventive strategies and comprehensive disease management. Am Heart J.1997,133(6):703-712.
[6]Massie BM, Shah NB. The heart failure epidemic:magnitude of the problem and potential mitigating approaches. Curr Opin Cardiol,1996,11(3):221-226.
[7]Dahms NM, Hancock MK. P-type lectins. Biochim Biophys Acta.2002,1572(2): 317-340.
[8]Lobel P, Dahms N M, Kornfeld S. Cloning and sequence analysis of the cation-independent mannose 6-phosphate receptor. J BiolChem.1988,263(5):2563-2570.
[9]Pavelic K, Bukovic D, Pavelic J.The Role of Insulin-Like Growth Factor 2 and Its Receptors in Human Tumors. Mol Med.2002,8(12):771-780.
[10]Scott, C. D, Baxter, R. C. Regulation of soluble insulin-like growth factor-II/ mannose 6-phosphate receptor in hepatocytes from intact and regenerating rat liver.Endocrinology.1996,137(9):3864-3870
[11]Hebert E. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep.2006(1),26:7-17.
[12]Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P, Stewart CL. Loss of the imprinted IGF2/cation-independent mannose6-phosphate receptor results in fetal overgrowth and perinatal lethality. Gene Dev.1994,8(24):2953-2963.
[13]Ludwig T, Eggenschwiler J, Fisher P, D'Ercole AJ, Davenport ML, Efstratiadis A.Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igflr null backgrounds.Dev Biol.1996,177(2):517-35.
[14]Wang ZQ, Fung MR, BarlowD. P, Wagner, E. F.Regulation of embryonic growth and lysosomal targeting by the imprinted IGF2/MPR gene. Nature 1994,372 (6505),464-467.
[15]Godar S, Horejsi V, Weidle UH, Binder BR, Hansmann C, Stockinger H.M6P/ IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-βl.Eur J Immunol.1999.29(3):1004-1013.
[16]Chang MH, Kuo WW, Chen RJ, Lu MC, Tsai FJ, Kuo WH, Chen LY, Wu WJ, Huang CY, Chu CH. IGF-II/mannose 6-phosphate receptor activation inducesmetalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.J Mol Endocrinol.2008,41(2):65-74.
[17]Su W, Zhang H, Jia Z, Zhou C, Wei Y, Hu S. Cartilage-derived stromal cells:is it a novel cell resource for cell therapy to regenerate infarcted myocardium?.Stem Cells. 2006,24(2):349-356.
[18]Zhu W, Chen J, Cong X, Hu S, Chen X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells.Stem Cells.2006,24(2):416-25.
[19]Simpson P, McGrath A, Savison S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines.Circ Res.1982,51(6): 787-801.
[20]周晓霞,陈兰英,血管紧张素Ⅱ对培养心肌细胞蛋白质和DAN的影响。细胞生物学杂志。1995,17(1)：37-40
[21]Jones JI, Clemmons DR.Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev.1995,16(1):3-34.
[22]Vasylyeva TL, Ferry RJ Jr. Novel roles of the IGF-IGFBP axis in tiopathophysiology of diabetic nephropathy.Diabetes Res Clin Pract.2007,76(2): 177-186.
[23]O'Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R, Blattler WA. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol,1997,17(l):427-435.
[24]Boker C, von Figura K, Hille-Rehfeld A.The carboxy-terminal peptides of 46 kDa and 300 kDa mannose 6-phosphate receptors share partial sequence homology and contain information for sorting in the early endosomal pathway[J]. Journal of Cell Science.1997,110(8):1023-1032.
[25]Kotlyar AA, Vered Z, Goldberg I, Chouraqui P, Nas D, Fridman E, Chen-Levy Z, Fytlovich S, Sangiorgi Q Spagnoli LG, Orlandi A, Savion N, Eldar M, Scheinowitz M.Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine. Heart 2001,86(6):693-700.
[26]Vogt AM, Htun P, Kluge A, Zimmermann R, Schaper W.Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery
occlusion.Cardiovascular Research.1997.33(2).469-477.
[27]K luge A, Zimmermann R, Miinkel B, Verdouw PD, Schaper J, Schaper W. Insulin-like growth factor II is an experimental stress inducible gene in a porcine model of brief coronary occlusions. Cardiovasc Res.1995,29(5):708-16.
[28]Yellon DM, Latchman DS. Stress proteins and myocardial protection.J Mol Cell Cardiol.1992,24(2):113-24.
[29]Ewton DZ, Falen SL, Florini JR. The type II insulin-like growth factor (IGF) receptor has low affinity for IGF-I analogs:pleiotypic actions of IGFs on myoblasts are apparently mediated by the type I receptor.Endocrinology.1987,120(1):115-23.
[30]Neff NT, Prevette D, Houenou LJ, Lewis ME, Glicksman MA, Yin QW, Oppenheim RW.Insulin-like growth factors:putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol.1993,24(12):1578-88.
[31]Clairmont KB, Czech MP.Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J. Biol Chem.1991. 266(19):12131-12134
[32]Lee SD, Chu CH, Huang EJ, Lu MC, Liu JY, Liu CJ, Hsu HH, Lin JA, Kuo WW, Huang CY.Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation. Am J Physiol Endocrinol Metab, 2006,291(2):E306-314.
[33]Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M.Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes.Circ Res.1994 75(3):426-33
[34]Yaniv G, Shilkrut M, Lotan R, Berke G, Larisch S, Binah O. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Cardiovascular Research.2002,54(3),611-623.
[35]Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes.J Clin Invest.1994,94(4):1621-8.
[36]Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.Mol Cell Biol.1999, 19(5):3278-3288.
[37]Wang ZQ, Fung MR, Barlow DP, Wagner EF. Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/MPR gene.Nature.1994,372 (6505):
464-7.
[38]Chu CH, Tzang BS, Chen LM, Liu CJ, Tsai FJ, Tsai CH, Lin JA, Kuo WW, Bau DT, Yao CH, Huang CY.Activation of IGF2R induces Mitochondrial-dependent Apoptosis through Gaq and Downstream Calcineurin Signaling in Myocardial Cells.Endocrinology.2009,150 (6):2723-31.
[1]Jones JI, Clemmons D R.Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev.1995,16(1):3-34.
[2]Vasylyeva TL, Ferry RJ Jr. Novel roles of the IGF-IGFBP axis in tiopathophysiology of diabetic nephropathy.Diabetes Res Clin Pract.2007,76(2):177-186.
[3]Dahms NM, Hancock MK. P-type lectins. Biochim Biophys Acta.2002,1572(2): 317-340.
[4]Lobel P, Dahms N M, Kornfeld S. Cloning and sequence analysis of the cation-independent mannose 6-phosphate receptor. J BiolChem.1988,263(5):2563-2570.
[5]Hancock MK,Haskins DJ,Sun G, Dahms NM.Identification of residues essential for carbohydrate recognitionby the insulin-like growth factor Ⅱ/mannose 6-phosphatereceptor. J Biol Chem.2002,277(13):11255-64.
[6]Marron-Terada PG, Hancock MK, Haskins DJ, Dahms NM. Recognition of Dictyostelium discoideum lysosomal enzymes is conferred by the amino-terminalcarbohydrate binding site of the insulin-like growth factor II/mannose 6-phosphate receptor. Biochemistry.2000,39(9):2243-2253.
[7]Schmidt B, Kiecke-Siemsen C, Waheed A, Braulke T, von Figura K. Localization of the insulin-like growth factor IIbinding site to amino acids 1508-1566 in repeat 11 of themannose 6-phosphate/insulin-like growth factor Ⅱ receptor. J Biol Chem.1995, 270(25):14975-14982.
[8]Korner C,Nurnberg B,Uhde M,Braulke T.Mannose6Phosphate/insulin-like growth factor II receptor fails to interact with Gproteins,an alysis of mutant cytoplasmic receptor domains.J Biol Chem.1995,270(1):287-295.
[9]Gelato MC, Rutherford C, Stark RI, Daniel SS. The insulin-like growth factor II/mannose-6-phosphate receptor is present in fetal and maternal sheep serum. Endocrinology,1989,124(6):2935-2943.
[10]Xu Y, Papageorgiou A, Polychronakos C. Developmental regulation of the soluble form of insulin-like growth factor-II/mannose 6-phosphate receptor in human serum and amniotic fluid. J Clin Endocrinol Metab.1998,83(2):437-442.
[11]Clairmont KB, Czech MP.Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J. Biol.Chem.1991, 266(19):12131-12134.
[12]Scott CD, Baxter RC.Regulation of soluble insulin-like growth factor-II/mannose 6-phosphate receptor in hepatocytes from intact and regenerating rat liver. Endocrinology.1996,137(9):3864-3870.
[13]Bobek G, Scott CD, Baxter RC. Secretion of soluble insulin-like growth factor-Ⅱ/mannose 6-phosphate receptor by rat tissues in culture.Endocrinology 1991, 128(4):2204-2206.
[14]Scott C D, Weiss J. Soluble insulin-like growth factor II/mannose 6-phosphate receptor inhibits DNA synthesis in insulin-like growth factor II sensitive cells. J. Cell.Physiol.2000,182(1):62-68.
[15]Costello M, Baxter RC, Scott CD. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum:Measurement by enzyme-linked immunosorbent assay. J Clin Endocrinol Metab.1999,84(2):611-617.
[16]Clairmont KB, Czech MP.Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J. Biol Chem.1991. 266(19):12131-12134.
[17]Zaina S, Squire S. The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms.J. Biol. Chem.1998,273(44):610-28616.
[18]Scott C D, Baxter R C,Regulation of soluble insulin-like growth factor-Ⅱ/annose 6-phosphate receptor in hepatocytes from intact and regenerating rat liver.Endocrinology.1996,37(9):3864-3870.
[19]Reddy ST, Chai W, Childs RA, Page JD, Feizi T, Dahms NM. Identification of a low afinity mannose 6-phosphate-binding site in domaln 5 of the cation-independent mannose 6-phosphate receptor.J Biol Chem.2004,9(37):38658-38667.
[20]Olson LJ,Dahms NM,Kim JJ.The N-terminal carbohydrate recognition site of the cation-independent mannose6-phosphate receptor. J Biol Chem.2004,279(32): 34000-34009.
[21]Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF, Gauldie J, Bleackley RC.Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell.2000,103(3):491-500.
[22]Brown J, Esnouf R M, Jones M A, et al. Structure offunctional IGF2R fragment determined from the anomalous scattering of sulfur. EMBO J.2002,21(5):1054-1062.
[23]Brown J, Esnouf RM, Jones MA, Linnell J, Harlos K, Hassan AB, Jones EY. Real time kinetics of insulinlike growth factor II(IGF-II)interaction with theIGF2/mannose 6 phosphate receptor: the effects of domain 13 and pH. Biol Chem.2001,76(26):23986-91.
[24]Dahms NM, Brzycki-Wessell MA, Ramanujam KS, Seetharam B. Characterization of mannose6-phosphate receptors (MPRs) from opossum liver: opossum cation-independent MPR binds insulin-like growth factor-II.Endocrinology.1993,133 (2):440-446.
[25]Yandell CA, Dunbar AJ, Wheldrake JF, Upton Z.The kangaroo cation-independent mannose 6-phosphate receptor binds insulin-like growth factor2 with low affinity.J Biol Chem.1999,274(38):27076-27082.
[26]Clairmont K B,Czech M P.Chicken and Xenopus mannose 6-phosphate receptors fail to bind insulin-like growth factorⅡ.J Biol Chem.1989,264(28):16390-16392.
[27]Mendez E, Planas JV, Castillo J, Navarro I, Gutierrez J. Identification of a type II insulin-like growth factor receptor in fish embryos.Endocrinology.2001,142(3): 1090-1097.
[28]Laureys G, Barton DE, Ullrich A, Francke U. Chromosomal mapping of the gene for the type II insulin-like growth factor receptor/cation-independent mannose6-phosphate receptor in man and mouse.Genomics.1988,3(3):224-229.
[29]Szebenyi G, RotweinP.The mouse insulin-like growth factor Ⅱ/cation-independent mannose 6-phosphate (IGF-II/MPR) receptor gene: Molecular cloning and genomic organization. Genomics.1994,19(1):120-129.
[30]Killian JK, Jirtle, R. Genomic structure of the human M6P/IGF2 receptor.Mamm. Genome.1999,10(1):74-77.
[31]Kalscheuer VM, Mariman EC, Schepens MT, Rehder H, Ropers HH. The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. Nat. Genet.1993,5(1):74-78.
[32]Liu Z, Mittanck DW, Kim S, Rotwein P. Control of insulin-like growth factor-Ⅱ/mannose 6-phosphate receptor gene transcription by proximal promoter elements. Mol.Endocrinol.1995,9(11):1477-1487.
[33]Braulke, T. Type-2 IGF receptor: A multi-ligand binding protein. Horm Metab. Res.1999,31(2-3):242-246.
[34]Hawkes C, Kar S.The insulin-like growth factor-Ⅱ/mannose-6-phosphatereceptor: Structure, distribution and function in the central nervous system. Brain Res Rev. 2004,44(2-3):117-140.
[35]Stewart CE, Rotwein P. Growth, differentiation and survival:multiple physiological functions of insulin-like growth factors. Physiol Rev.1996,76(4):1005-1026.
[36]LeRoith D. Seminars in medicine of the Beth Israel Deaconess Medical Center.
Insulin-like growth factors. N Engl J Med.1997,336:633-640.
[37]Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R.Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol.1999, 19(5):3278-3288.
[38]Ashton IK, Zapf J, Einschenk I, MacKenzie IZ. Insulin-like growth factors(IGF) 1 and 2 in human foetal plasma and relationship to gestational age and foetal size during midpregnancy. Acta Endocrinol.1985,110(4):558-563.
[39]DeChiara TM, Efstradiatis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature.1990,345(6270):78-80.
[40]Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P, Stewart CL.Loss of the imprinted IGF2/cation-independent mannose6-phosphate receptor results in fetal overgrowth and perinatal lethality. Gene Dev.1994,8(24):2953-2963.
[41]Ludwig T, Eggenschwiler J, Fisher P.Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in IGF2 and IGF1R null backgrounds. Dev Biol.1996,177(2),517-535.
[42]Wang ZQ, Fung MR, BarlowD. P, Wagner, E. F.Regulation of embryonic growth and lysosomal targeting by the imprinted IGF2/MPR gene. Nature 1994.372(6505), 464-467.
[43]Chen Zhihong, Ge Yinlin, Jing X Kang. Down-regulation of the M6P/IGF-II receptor increase cell proliferation and reduces apoptosis in neonatal rat cardiac myocytes. BMC Cell Biol.2004,28(4):5-15.
[44]McKinnon, T., Chakraborty, C., Gleeson, L. M., Chidiac, P. Lala, P. K. Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. J. Clin. Endocrinol Metab.2001,86(8):3665-3674.
[45]Groskopf, J. C., Syu, L. J., Saltiel, A. R. Linzer, D. I.Proliferin induces endothelial cell chemotaxis through a G protein-coupled, mitogen-activated protein kinase-dependent pathway.Endocrinology.1997,138(7):2835-2840.
[46]Minniti CP, Kohn EC, Grubb JH, Sly WS, Oh Y, Miiller HL, Rosenfeld RG, Helman LJ. The insulin-like growth factor II (IGF-Ⅱ)/mannose 6-phosphate receptor mediates IGF-Ⅱ-induced motility in human rhabdomyosarcoma cells.J.Biol.Chem.1992,267(13):9000-9004.
[47]Zhang Q, Tally M, Larsson O, Kennedy RT, Huang L, Hall K, Berggren PO.
Insulin-like growth factor-II signaling through the insulin like growth factor-Ⅱ/mannose 6-phosphate receptor promotes exocytosis of insulin-secreting cells.Proc Natl Acad Sci USA.1997,94(12):6232-6237.
[48]Ikezu T, Okamoto T, Giambarella U, Yokota T, Nishimoto I.In vivo coupling of insulin-like growth factor II/mannose 6-phosphate receptor to heteromeric G proteins. Distinct roles of cytoplasmic domains and signal sequestration by the receptor.J Biol Chem.1995,270(49):29224-29228
[49]Hawkes, C., Amritraj, A., Macdonald, R. G., Jhamandas, J. H., Kar, S.Heterotrimeric G proteins and the single-transmembrane domain IGF-II/M6P receptor: Functional interaction and relevance to cell signaling. Mol. Neurobiol. 2007,35(3):329-345.
[50]El-Shewy, H. M., Johnson, K. R., Lee, M. H., Jaffa, A. A., Obeid, L. M., Luttrell, L. M.. Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2activation by transactivating sphingosine 1-phosphate receptors. J. Biol. Chem.2006,281(42):1399-31407.
[51]El-Shewy, H. M., Lee, M. H., Obeid, L. M., Jaffa, A. A., Luttrell, L. M. The insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells. J. Biol.Chem.2007,282(36):26150-26157.
[52]Hebert, E. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep.2006,26(1):7-17.
[53]Massague, J., Wotton, D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J.2000,19(8):1745-1754.
[54]Jang, H. S., Kang, K. M., Choi, B. O., Chai, G. Y., Hong, S. C., Ha, W. S., Jirtle, R. L.. Clinical significance of loss of heterozygosity for M6P/IGF2R in patients withprimary hepatocellular carcinoma. World J. Gastroenterol.2008,14(9):1394-1398.
[55]Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, Jirtle RL M6P/IGF2 receptor: a candidatebreast tumor suppressor gene. Oncogene.1996, 12(9):2003-2009.
[56]Chappell, S. A., Walsh, T., Walker, R. A. Shaw, J. A. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br. J. Cancer.1997,76(12):1558-1561.
[57]Kong, F. M., Anscher, M. S., Washington, M. K., Killian, J. K.Jirtle, R. L.M6P/IGF2R is mutated in squamous cellcarcinoma of the lung. Oncogene.2000, 19(12):1572-1578
[58]Rey, J. M., Theillet, C., Brouillet, J. P. Rochefort, H. Stable amino-acid sequence of the mannose-6-phosphate/insulinlike growth-factor-II receptor in ovarian carcinomas with loss of heterozygosity and in breast cancer cell lines.Int. J. Cancer.2000, 85(4):466-473
[59]Huang, Z., Wen, Y., Shandilya, R., Marks, J. R., Berchuck, A., Murphy, S. K. High throughput detection of M6P/IGF2R intronic hypermethylation and LOH inovarian cancer. Nucleic Acids Res.2006,34(2):555-563.
[60]Leboulleux, S., Gaston, V., Boulle, N., LeBouc, Y. Gicquel, C. Loss of heterozygosity at the mannose 6-phosphate/insulinlike growth factor receptor locus: a frequent but late event inadrenocortical tumorigenesis. Eur. J. Endocrinol.2001, 144(2):163-168.
[61]Hu, C. K., McCall, S., Madden, J., Huang, H., Clough, R., Jirtle, R. L., Anscher, M. S. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. Prostate Cancer Prostatic Dis.2006,9(1):62-67.
[62]Savage SA, Woodson K, Walk E, Modi W, Liao J, Douglass,et al. Analysis of genes critical for growth regulation identifies insulinlike growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma.Cancer Epidemiol. Biomarkers Prev.2007,16(8):1667-1674.
[63]Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat. Genet.1996,14(3): 255-257.
[64]Devi, G. R., De Souza, A. T., Byrd, J. C., Jirtle, R. L., MacDonald, R. G. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers. Cancer Res.1999,9(17):314-4319
[65]Byrd, J. C., Devi, G. R., de Souza, A. T., Jirtle, R. L., MacDonald, R. G. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphatereceptor by cancer-associated missense mutations. J. Biol. Chem.1999,274(34): 24408-24416.
[66]O'Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD.Insulin like growth factor-Ⅱ/mannose 6-phosphate receptor overexpression reduces growth ofchoriocarcinoma cells in vitro and in vivo.Endocrinology.2002,143(11): 4287-4294.
[67]Lee, J. S., Weiss, J., Martin, J. L., Scott, C. D. Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int. J. Cancer.2003,107(4):564-570.
[68]Prince SN, Foulstone EJ, Zaccheo OJ, Williams C, Hassan AB. Functional evaluation of novel soluble insulin-like growth factor (IGF)-Ⅱ-specific ligand traps based on modified domain 11 of the human IGF2 receptor.Mol Cancer Ther.2007, 6(2):607-617.
[69]Kotlyar AA, Vered Z, Goldberg I, Chouraqui P, Nas D, Fridman,Insulin-like growth factor I and Ⅱ preserve myocardial structure in postinfarct swine. Heart 2001, 86(6):693-700.
[70]Achim M. Vogt, Patrik Htun, Angelika Kluge, Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery occlusion. Cardiovascular Research.1997,33(2):469-477.
[71]Chang MH, Kuo WW, Chen RJ, Lu MC, Tsai FJ, Kuo WH, Chen LY, Wu WJ, Huang CY, Chu CH. IGF-Ⅱ/mannose 6-phosphate receptor activation inducesmetalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.J Mol Endocrinol.2008,41(2):65-74.
[72]Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rational for preventive strategies and comprehensive disease management. Am Heart J.1997,133(6):703-712.
[73]Massie BM, Shah NB. The heart failure epidemic:magnitude of the problem and potential mitigating approaches. Curr Opin Cardiol,1996,11(3):221-226.
[74]Godar S, Horejsi V, Weidle UH, Binder BR, Hansmann C, Stockinger H.M6P/
IGFII-receptor complexes urokinase receptor and plasminogen for activation of
transforming growth factor-β1.Eur J Immunol.1999.29(3):1004-1013.
[75]Lee SD, Chu CH, Huang EJ, Lu MC, Liu JY, Liu CJ, Hsu HH, Lin JA, Kuo WW, Huang CY.Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation. Am J Physiol Endocrinol Metab, 2006,291(2):E306-314.
[76]Chu CH, Tzang BS, Chen LM, Liu CJ, Tsai FJ, Tsai CH, Lin JA, Kuo WW, Bau DT, Yao CH, Huang CY.Activation of IGF2R induces Mitochondrial-dependent Apoptosis through Gaq and Downstream Calcineurin Signaling in Myocardial Cells.Endocrinology.2009,150 (6):2723-31.
[77]Chu CH, Tzang BS, Chen LM, Kuo CH, Cheng YC, Chen LY, Tsai FJ, Tsai CH, Kuo WW, Huang CY.IGF-II/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via Gaq interaction and protein kinase C-a/CaMKII activation in H9c2 cardiomyoblast cells.Endocrinology, 2008,197(2):381-390.
[78].Dzau VJ, Brau-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis:new perspectives and therapeutic strategies. Nature Med.2002, 8(11):1249-1256.
[79]Zaina S, Pettersson L, Ahren B, Branen L, Hassan AB, Lindholm M, Mattsson R, Thyberg J, Nilsson J.Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model. J Biol Chem.2002,277(6):4505-4511.
[80]Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K, Hintz R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem.1994,269(19): 13779-13784.
[81]Da Costa TH, Williamson DH, Ward A, Bates P, Fisher R, Richardson L, Graham CF. High plasma insulin-like growth factor-II and low lipid content in transgenic mice: measurement of lipid metabolism. J Endocrinol.1994,143(3):433-439.
[82]Zaina S, Pettersson L, Ahren B, Branen L, Hassan AB, Lindholm M, Mattsson R, Thyberg J, Nilsson J. Insulin-like growth factor Ⅱ plays a central role in atherosclerosis in a mouse model. J Biol Chem 2002,277(6):4505-4511.
[83]Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pelegrin M, Gros L, Bosch F. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type2 diabetes. J Clin Invest 2000,105(6):731-740.
[84]Gibson JM, Westwood M, Young RJ, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996, 81(2):860-863.
[85]Libby P, Aikawa M. Stabilization of the atherosclerotic plaques:new mechanisms and clinical targets. Nat Med,2002,8(11):1257-1262.
[86]Mallat Z, Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives.Curr Opin Lipidol.2002,13(5):523-529.
[87]Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF, Gauldie J, Bleackley RC.Mannose 6-phosphate/insulin-like growth factor Ⅱ receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis.Cell.2000,103(3):491-500.
[88]Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A.1995,92(18):8264-8268.
[89]Ikari Y, McManus BM, Kenyon J, Schwartz SM.Neonatal intima formation in the human coronary artery.Arterioscler Thromb Vasc Biol.1999,19(9):2036-40.
[90]Schwartz SM. The intima: A new soil.Circ Res.1999,85(10):877-9.
[91]Weninger WJ, Muller GB, Reiter C, Meng S, Rabl SU. Intimal hyperplasia of the infant parasellar carotid artery: a potential developmental factor in atherosclerosis and SIDS.Circ Res.1999,85(10):970-5.
[2]Gibbons GH, Liew CC, Goodarzi MO, Rotter JI, Hsueh WA, Siragy HM, Pratt R, Dzau VJ. Genetic Markers:Progress and Potential for Cardiovascular Disease. Circulation.2004,109[suppl IV]:47-58.
[3]McGregor E, Dunn MJ. proteomics of the heart:unraveling disease. Circ Res.2006, 98(3): 309-321
[4]戴闺柱.慢性心力衰竭治疗的现代概念,[J]中华心血管病杂志。2000,28(1):75-78.
[5]Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rational for preventive strategies and comprehensive disease management. Am Heart J.1997,133(6):703-712.
[6]Massie BM, Shah NB. The heart failure epidemic:magnitude of the problem and potential mitigating approaches. Curr Opin Cardiol,1996,11(3):221-226.
[7]Dahms NM, Hancock MK. P-type lectins. Biochim Biophys Acta.2002,1572(2): 317-340.
[8]Lobel P, Dahms N M, Kornfeld S. Cloning and sequence analysis of the cation-independent mannose 6-phosphate receptor. J BiolChem.1988,263(5):2563-2570.
[9]Pavelic K, Bukovic D, Pavelic J.The Role of Insulin-Like Growth Factor 2 and Its Receptors in Human Tumors. Mol Med.2002,8(12):771-780.
[10]Scott, C. D, Baxter, R. C. Regulation of soluble insulin-like growth factor-II/ mannose 6-phosphate receptor in hepatocytes from intact and regenerating rat liver.Endocrinology.1996,137(9):3864-3870
[11]Hebert E. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep.2006(1),26:7-17.
[12]Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P, Stewart CL. Loss of the imprinted IGF2/cation-independent mannose6-phosphate receptor results in fetal overgrowth and perinatal lethality. Gene Dev.1994,8(24):2953-2963.
[13]Ludwig T, Eggenschwiler J, Fisher P, D'Ercole AJ, Davenport ML, Efstratiadis A.Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igflr null backgrounds.Dev Biol.1996,177(2):517-35.
[14]Wang ZQ, Fung MR, BarlowD. P, Wagner, E. F.Regulation of embryonic growth and lysosomal targeting by the imprinted IGF2/MPR gene. Nature 1994,372 (6505),464-467.
[15]Godar S, Horejsi V, Weidle UH, Binder BR, Hansmann C, Stockinger H.M6P/ IGFII-receptor complexes urokinase receptor and plasminogen for activation of transforming growth factor-βl.Eur J Immunol.1999.29(3):1004-1013.
[16]Chang MH, Kuo WW, Chen RJ, Lu MC, Tsai FJ, Kuo WH, Chen LY, Wu WJ, Huang CY, Chu CH. IGF-II/mannose 6-phosphate receptor activation inducesmetalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.J Mol Endocrinol.2008,41(2):65-74.
[17]Su W, Zhang H, Jia Z, Zhou C, Wei Y, Hu S. Cartilage-derived stromal cells:is it a novel cell resource for cell therapy to regenerate infarcted myocardium?.Stem Cells. 2006,24(2):349-356.
[18]Zhu W, Chen J, Cong X, Hu S, Chen X. Hypoxia and serum deprivation-induced apoptosis in mesenchymal stem cells.Stem Cells.2006,24(2):416-25.
[19]Simpson P, McGrath A, Savison S. Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines.Circ Res.1982,51(6): 787-801.
[20]周晓霞,陈兰英,血管紧张素Ⅱ对培养心肌细胞蛋白质和DAN的影响。细胞生物学杂志。1995,17(1)：37-40
[21]Jones JI, Clemmons DR.Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev.1995,16(1):3-34.
[22]Vasylyeva TL, Ferry RJ Jr. Novel roles of the IGF-IGFBP axis in tiopathophysiology of diabetic nephropathy.Diabetes Res Clin Pract.2007,76(2): 177-186.
[23]O'Connor R, Kauffmann-Zeh A, Liu Y, Lehar S, Evan GI, Baserga R, Blattler WA. Identification of domains of the insulin-like growth factor I receptor that are required for protection from apoptosis. Mol Cell Biol,1997,17(l):427-435.
[24]Boker C, von Figura K, Hille-Rehfeld A.The carboxy-terminal peptides of 46 kDa and 300 kDa mannose 6-phosphate receptors share partial sequence homology and contain information for sorting in the early endosomal pathway[J]. Journal of Cell Science.1997,110(8):1023-1032.
[25]Kotlyar AA, Vered Z, Goldberg I, Chouraqui P, Nas D, Fridman E, Chen-Levy Z, Fytlovich S, Sangiorgi Q Spagnoli LG, Orlandi A, Savion N, Eldar M, Scheinowitz M.Insulin-like growth factor I and II preserve myocardial structure in postinfarct swine. Heart 2001,86(6):693-700.
[26]Vogt AM, Htun P, Kluge A, Zimmermann R, Schaper W.Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery
occlusion.Cardiovascular Research.1997.33(2).469-477.
[27]K luge A, Zimmermann R, Miinkel B, Verdouw PD, Schaper J, Schaper W. Insulin-like growth factor II is an experimental stress inducible gene in a porcine model of brief coronary occlusions. Cardiovasc Res.1995,29(5):708-16.
[28]Yellon DM, Latchman DS. Stress proteins and myocardial protection.J Mol Cell Cardiol.1992,24(2):113-24.
[29]Ewton DZ, Falen SL, Florini JR. The type II insulin-like growth factor (IGF) receptor has low affinity for IGF-I analogs:pleiotypic actions of IGFs on myoblasts are apparently mediated by the type I receptor.Endocrinology.1987,120(1):115-23.
[30]Neff NT, Prevette D, Houenou LJ, Lewis ME, Glicksman MA, Yin QW, Oppenheim RW.Insulin-like growth factors:putative muscle-derived trophic agents that promote motoneuron survival. J Neurobiol.1993,24(12):1578-88.
[31]Clairmont KB, Czech MP.Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J. Biol Chem.1991. 266(19):12131-12134
[32]Lee SD, Chu CH, Huang EJ, Lu MC, Liu JY, Liu CJ, Hsu HH, Lin JA, Kuo WW, Huang CY.Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation. Am J Physiol Endocrinol Metab, 2006,291(2):E306-314.
[33]Tanaka M, Ito H, Adachi S, Akimoto H, Nishikawa T, Kasajima T, Marumo F, Hiroe M.Hypoxia induces apoptosis with enhanced expression of Fas antigen messenger RNA in cultured neonatal rat cardiomyocytes.Circ Res.1994 75(3):426-33
[34]Yaniv G, Shilkrut M, Lotan R, Berke G, Larisch S, Binah O. Hypoxia predisposes neonatal rat ventricular myocytes to apoptosis induced by activation of the Fas (CD95/Apo-1) receptor: Fas activation and apoptosis in hypoxic myocytes. Cardiovascular Research.2002,54(3),611-623.
[35]Gottlieb RA, Burleson KO, Kloner RA, Babior BM, Engler RL. Reperfusion injury induces apoptosis in rabbit cardiomyocytes.J Clin Invest.1994,94(4):1621-8.
[36]Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R. Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells.Mol Cell Biol.1999, 19(5):3278-3288.
[37]Wang ZQ, Fung MR, Barlow DP, Wagner EF. Regulation of embryonic growth and lysosomal targeting by the imprinted Igf2/MPR gene.Nature.1994,372 (6505):
464-7.
[38]Chu CH, Tzang BS, Chen LM, Liu CJ, Tsai FJ, Tsai CH, Lin JA, Kuo WW, Bau DT, Yao CH, Huang CY.Activation of IGF2R induces Mitochondrial-dependent Apoptosis through Gaq and Downstream Calcineurin Signaling in Myocardial Cells.Endocrinology.2009,150 (6):2723-31.
[1]Jones JI, Clemmons D R.Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev.1995,16(1):3-34.
[2]Vasylyeva TL, Ferry RJ Jr. Novel roles of the IGF-IGFBP axis in tiopathophysiology of diabetic nephropathy.Diabetes Res Clin Pract.2007,76(2):177-186.
[3]Dahms NM, Hancock MK. P-type lectins. Biochim Biophys Acta.2002,1572(2): 317-340.
[4]Lobel P, Dahms N M, Kornfeld S. Cloning and sequence analysis of the cation-independent mannose 6-phosphate receptor. J BiolChem.1988,263(5):2563-2570.
[5]Hancock MK,Haskins DJ,Sun G, Dahms NM.Identification of residues essential for carbohydrate recognitionby the insulin-like growth factor Ⅱ/mannose 6-phosphatereceptor. J Biol Chem.2002,277(13):11255-64.
[6]Marron-Terada PG, Hancock MK, Haskins DJ, Dahms NM. Recognition of Dictyostelium discoideum lysosomal enzymes is conferred by the amino-terminalcarbohydrate binding site of the insulin-like growth factor II/mannose 6-phosphate receptor. Biochemistry.2000,39(9):2243-2253.
[7]Schmidt B, Kiecke-Siemsen C, Waheed A, Braulke T, von Figura K. Localization of the insulin-like growth factor IIbinding site to amino acids 1508-1566 in repeat 11 of themannose 6-phosphate/insulin-like growth factor Ⅱ receptor. J Biol Chem.1995, 270(25):14975-14982.
[8]Korner C,Nurnberg B,Uhde M,Braulke T.Mannose6Phosphate/insulin-like growth factor II receptor fails to interact with Gproteins,an alysis of mutant cytoplasmic receptor domains.J Biol Chem.1995,270(1):287-295.
[9]Gelato MC, Rutherford C, Stark RI, Daniel SS. The insulin-like growth factor II/mannose-6-phosphate receptor is present in fetal and maternal sheep serum. Endocrinology,1989,124(6):2935-2943.
[10]Xu Y, Papageorgiou A, Polychronakos C. Developmental regulation of the soluble form of insulin-like growth factor-II/mannose 6-phosphate receptor in human serum and amniotic fluid. J Clin Endocrinol Metab.1998,83(2):437-442.
[11]Clairmont KB, Czech MP.Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J. Biol.Chem.1991, 266(19):12131-12134.
[12]Scott CD, Baxter RC.Regulation of soluble insulin-like growth factor-II/mannose 6-phosphate receptor in hepatocytes from intact and regenerating rat liver. Endocrinology.1996,137(9):3864-3870.
[13]Bobek G, Scott CD, Baxter RC. Secretion of soluble insulin-like growth factor-Ⅱ/mannose 6-phosphate receptor by rat tissues in culture.Endocrinology 1991, 128(4):2204-2206.
[14]Scott C D, Weiss J. Soluble insulin-like growth factor II/mannose 6-phosphate receptor inhibits DNA synthesis in insulin-like growth factor II sensitive cells. J. Cell.Physiol.2000,182(1):62-68.
[15]Costello M, Baxter RC, Scott CD. Regulation of soluble insulin-like growth factor II/mannose 6-phosphate receptor in human serum:Measurement by enzyme-linked immunosorbent assay. J Clin Endocrinol Metab.1999,84(2):611-617.
[16]Clairmont KB, Czech MP.Extracellular release as the major degradative pathway of the insulin-like growth factor II/mannose 6-phosphate receptor. J. Biol Chem.1991. 266(19):12131-12134.
[17]Zaina S, Squire S. The soluble type 2 insulin-like growth factor (IGF-II) receptor reduces organ size by IGF-II-mediated and IGF-II-independent mechanisms.J. Biol. Chem.1998,273(44):610-28616.
[18]Scott C D, Baxter R C,Regulation of soluble insulin-like growth factor-Ⅱ/annose 6-phosphate receptor in hepatocytes from intact and regenerating rat liver.Endocrinology.1996,37(9):3864-3870.
[19]Reddy ST, Chai W, Childs RA, Page JD, Feizi T, Dahms NM. Identification of a low afinity mannose 6-phosphate-binding site in domaln 5 of the cation-independent mannose 6-phosphate receptor.J Biol Chem.2004,9(37):38658-38667.
[20]Olson LJ,Dahms NM,Kim JJ.The N-terminal carbohydrate recognition site of the cation-independent mannose6-phosphate receptor. J Biol Chem.2004,279(32): 34000-34009.
[21]Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF, Gauldie J, Bleackley RC.Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis. Cell.2000,103(3):491-500.
[22]Brown J, Esnouf R M, Jones M A, et al. Structure offunctional IGF2R fragment determined from the anomalous scattering of sulfur. EMBO J.2002,21(5):1054-1062.
[23]Brown J, Esnouf RM, Jones MA, Linnell J, Harlos K, Hassan AB, Jones EY. Real time kinetics of insulinlike growth factor II(IGF-II)interaction with theIGF2/mannose 6 phosphate receptor: the effects of domain 13 and pH. Biol Chem.2001,76(26):23986-91.
[24]Dahms NM, Brzycki-Wessell MA, Ramanujam KS, Seetharam B. Characterization of mannose6-phosphate receptors (MPRs) from opossum liver: opossum cation-independent MPR binds insulin-like growth factor-II.Endocrinology.1993,133 (2):440-446.
[25]Yandell CA, Dunbar AJ, Wheldrake JF, Upton Z.The kangaroo cation-independent mannose 6-phosphate receptor binds insulin-like growth factor2 with low affinity.J Biol Chem.1999,274(38):27076-27082.
[26]Clairmont K B,Czech M P.Chicken and Xenopus mannose 6-phosphate receptors fail to bind insulin-like growth factorⅡ.J Biol Chem.1989,264(28):16390-16392.
[27]Mendez E, Planas JV, Castillo J, Navarro I, Gutierrez J. Identification of a type II insulin-like growth factor receptor in fish embryos.Endocrinology.2001,142(3): 1090-1097.
[28]Laureys G, Barton DE, Ullrich A, Francke U. Chromosomal mapping of the gene for the type II insulin-like growth factor receptor/cation-independent mannose6-phosphate receptor in man and mouse.Genomics.1988,3(3):224-229.
[29]Szebenyi G, RotweinP.The mouse insulin-like growth factor Ⅱ/cation-independent mannose 6-phosphate (IGF-II/MPR) receptor gene: Molecular cloning and genomic organization. Genomics.1994,19(1):120-129.
[30]Killian JK, Jirtle, R. Genomic structure of the human M6P/IGF2 receptor.Mamm. Genome.1999,10(1):74-77.
[31]Kalscheuer VM, Mariman EC, Schepens MT, Rehder H, Ropers HH. The insulin-like growth factor type-2 receptor gene is imprinted in the mouse but not in humans. Nat. Genet.1993,5(1):74-78.
[32]Liu Z, Mittanck DW, Kim S, Rotwein P. Control of insulin-like growth factor-Ⅱ/mannose 6-phosphate receptor gene transcription by proximal promoter elements. Mol.Endocrinol.1995,9(11):1477-1487.
[33]Braulke, T. Type-2 IGF receptor: A multi-ligand binding protein. Horm Metab. Res.1999,31(2-3):242-246.
[34]Hawkes C, Kar S.The insulin-like growth factor-Ⅱ/mannose-6-phosphatereceptor: Structure, distribution and function in the central nervous system. Brain Res Rev. 2004,44(2-3):117-140.
[35]Stewart CE, Rotwein P. Growth, differentiation and survival:multiple physiological functions of insulin-like growth factors. Physiol Rev.1996,76(4):1005-1026.
[36]LeRoith D. Seminars in medicine of the Beth Israel Deaconess Medical Center.
Insulin-like growth factors. N Engl J Med.1997,336:633-640.
[37]Frasca F, Pandini G, Scalia P, Sciacca L, Mineo R, Costantino A, Goldfine ID, Belfiore A, Vigneri R.Insulin receptor isoform A, a newly recognized, high-affinity insulin-like growth factor II receptor in fetal and cancer cells. Mol Cell Biol.1999, 19(5):3278-3288.
[38]Ashton IK, Zapf J, Einschenk I, MacKenzie IZ. Insulin-like growth factors(IGF) 1 and 2 in human foetal plasma and relationship to gestational age and foetal size during midpregnancy. Acta Endocrinol.1985,110(4):558-563.
[39]DeChiara TM, Efstradiatis A, Robertson EJ. A growth-deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by targeting. Nature.1990,345(6270):78-80.
[40]Lau MM, Stewart CE, Liu Z, Bhatt H, Rotwein P, Stewart CL.Loss of the imprinted IGF2/cation-independent mannose6-phosphate receptor results in fetal overgrowth and perinatal lethality. Gene Dev.1994,8(24):2953-2963.
[41]Ludwig T, Eggenschwiler J, Fisher P.Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in IGF2 and IGF1R null backgrounds. Dev Biol.1996,177(2),517-535.
[42]Wang ZQ, Fung MR, BarlowD. P, Wagner, E. F.Regulation of embryonic growth and lysosomal targeting by the imprinted IGF2/MPR gene. Nature 1994.372(6505), 464-467.
[43]Chen Zhihong, Ge Yinlin, Jing X Kang. Down-regulation of the M6P/IGF-II receptor increase cell proliferation and reduces apoptosis in neonatal rat cardiac myocytes. BMC Cell Biol.2004,28(4):5-15.
[44]McKinnon, T., Chakraborty, C., Gleeson, L. M., Chidiac, P. Lala, P. K. Stimulation of human extravillous trophoblast migration by IGF-II is mediated by IGF type 2 receptor involving inhibitory G protein(s) and phosphorylation of MAPK. J. Clin. Endocrinol Metab.2001,86(8):3665-3674.
[45]Groskopf, J. C., Syu, L. J., Saltiel, A. R. Linzer, D. I.Proliferin induces endothelial cell chemotaxis through a G protein-coupled, mitogen-activated protein kinase-dependent pathway.Endocrinology.1997,138(7):2835-2840.
[46]Minniti CP, Kohn EC, Grubb JH, Sly WS, Oh Y, Miiller HL, Rosenfeld RG, Helman LJ. The insulin-like growth factor II (IGF-Ⅱ)/mannose 6-phosphate receptor mediates IGF-Ⅱ-induced motility in human rhabdomyosarcoma cells.J.Biol.Chem.1992,267(13):9000-9004.
[47]Zhang Q, Tally M, Larsson O, Kennedy RT, Huang L, Hall K, Berggren PO.
Insulin-like growth factor-II signaling through the insulin like growth factor-Ⅱ/mannose 6-phosphate receptor promotes exocytosis of insulin-secreting cells.Proc Natl Acad Sci USA.1997,94(12):6232-6237.
[48]Ikezu T, Okamoto T, Giambarella U, Yokota T, Nishimoto I.In vivo coupling of insulin-like growth factor II/mannose 6-phosphate receptor to heteromeric G proteins. Distinct roles of cytoplasmic domains and signal sequestration by the receptor.J Biol Chem.1995,270(49):29224-29228
[49]Hawkes, C., Amritraj, A., Macdonald, R. G., Jhamandas, J. H., Kar, S.Heterotrimeric G proteins and the single-transmembrane domain IGF-II/M6P receptor: Functional interaction and relevance to cell signaling. Mol. Neurobiol. 2007,35(3):329-345.
[50]El-Shewy, H. M., Johnson, K. R., Lee, M. H., Jaffa, A. A., Obeid, L. M., Luttrell, L. M.. Insulin-like growth factors mediate heterotrimeric G protein-dependent ERK1/2activation by transactivating sphingosine 1-phosphate receptors. J. Biol. Chem.2006,281(42):1399-31407.
[51]El-Shewy, H. M., Lee, M. H., Obeid, L. M., Jaffa, A. A., Luttrell, L. M. The insulin-like growth factor type 1 and insulin-like growth factor type 2/mannose-6-phosphate receptors independently regulate ERK1/2 activity in HEK293 cells. J. Biol.Chem.2007,282(36):26150-26157.
[52]Hebert, E. Mannose-6-phosphate/insulin-like growth factor II receptor expression and tumor development. Biosci Rep.2006,26(1):7-17.
[53]Massague, J., Wotton, D. Transcriptional control by the TGF-beta/Smad signaling system. EMBO J.2000,19(8):1745-1754.
[54]Jang, H. S., Kang, K. M., Choi, B. O., Chai, G. Y., Hong, S. C., Ha, W. S., Jirtle, R. L.. Clinical significance of loss of heterozygosity for M6P/IGF2R in patients withprimary hepatocellular carcinoma. World J. Gastroenterol.2008,14(9):1394-1398.
[55]Hankins GR, De Souza AT, Bentley RC, Patel MR, Marks JR, Iglehart JD, Jirtle RL M6P/IGF2 receptor: a candidatebreast tumor suppressor gene. Oncogene.1996, 12(9):2003-2009.
[56]Chappell, S. A., Walsh, T., Walker, R. A. Shaw, J. A. Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor gene correlates with poor differentiation in early breast carcinomas. Br. J. Cancer.1997,76(12):1558-1561.
[57]Kong, F. M., Anscher, M. S., Washington, M. K., Killian, J. K.Jirtle, R. L.M6P/IGF2R is mutated in squamous cellcarcinoma of the lung. Oncogene.2000, 19(12):1572-1578
[58]Rey, J. M., Theillet, C., Brouillet, J. P. Rochefort, H. Stable amino-acid sequence of the mannose-6-phosphate/insulinlike growth-factor-II receptor in ovarian carcinomas with loss of heterozygosity and in breast cancer cell lines.Int. J. Cancer.2000, 85(4):466-473
[59]Huang, Z., Wen, Y., Shandilya, R., Marks, J. R., Berchuck, A., Murphy, S. K. High throughput detection of M6P/IGF2R intronic hypermethylation and LOH inovarian cancer. Nucleic Acids Res.2006,34(2):555-563.
[60]Leboulleux, S., Gaston, V., Boulle, N., LeBouc, Y. Gicquel, C. Loss of heterozygosity at the mannose 6-phosphate/insulinlike growth factor receptor locus: a frequent but late event inadrenocortical tumorigenesis. Eur. J. Endocrinol.2001, 144(2):163-168.
[61]Hu, C. K., McCall, S., Madden, J., Huang, H., Clough, R., Jirtle, R. L., Anscher, M. S. Loss of heterozygosity of M6P/IGF2R gene is an early event in the development of prostate cancer. Prostate Cancer Prostatic Dis.2006,9(1):62-67.
[62]Savage SA, Woodson K, Walk E, Modi W, Liao J, Douglass,et al. Analysis of genes critical for growth regulation identifies insulinlike growth factor 2 receptor variations with possible functional significance as risk factors for osteosarcoma.Cancer Epidemiol. Biomarkers Prev.2007,16(8):1667-1674.
[63]Souza RF, Appel R, Yin J, Wang S, Smolinski KN, Abraham JM et al. Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nat. Genet.1996,14(3): 255-257.
[64]Devi, G. R., De Souza, A. T., Byrd, J. C., Jirtle, R. L., MacDonald, R. G. Altered ligand binding by insulin-like growth factor II/mannose 6-phosphate receptors bearing missense mutations in human cancers. Cancer Res.1999,9(17):314-4319
[65]Byrd, J. C., Devi, G. R., de Souza, A. T., Jirtle, R. L., MacDonald, R. G. Disruption of ligand binding to the insulin-like growth factor II/mannose 6-phosphatereceptor by cancer-associated missense mutations. J. Biol. Chem.1999,274(34): 24408-24416.
[66]O'Gorman DB, Weiss J, Hettiaratchi A, Firth SM, Scott CD.Insulin like growth factor-Ⅱ/mannose 6-phosphate receptor overexpression reduces growth ofchoriocarcinoma cells in vitro and in vivo.Endocrinology.2002,143(11): 4287-4294.
[67]Lee, J. S., Weiss, J., Martin, J. L., Scott, C. D. Increased expression of the mannose 6-phosphate/insulin-like growth factor-II receptor in breast cancer cells alters tumorigenic properties in vitro and in vivo. Int. J. Cancer.2003,107(4):564-570.
[68]Prince SN, Foulstone EJ, Zaccheo OJ, Williams C, Hassan AB. Functional evaluation of novel soluble insulin-like growth factor (IGF)-Ⅱ-specific ligand traps based on modified domain 11 of the human IGF2 receptor.Mol Cancer Ther.2007, 6(2):607-617.
[69]Kotlyar AA, Vered Z, Goldberg I, Chouraqui P, Nas D, Fridman,Insulin-like growth factor I and Ⅱ preserve myocardial structure in postinfarct swine. Heart 2001, 86(6):693-700.
[70]Achim M. Vogt, Patrik Htun, Angelika Kluge, Insulin-like growth factor-II delays myocardial infarction in experimental coronary artery occlusion. Cardiovascular Research.1997,33(2):469-477.
[71]Chang MH, Kuo WW, Chen RJ, Lu MC, Tsai FJ, Kuo WH, Chen LY, Wu WJ, Huang CY, Chu CH. IGF-Ⅱ/mannose 6-phosphate receptor activation inducesmetalloproteinase-9 matrix activity and increases plasminogen activator expression in H9c2 cardiomyoblast cells.J Mol Endocrinol.2008,41(2):65-74.
[72]Massie BM, Shah NB. Evolving trends in the epidemiologic factors of heart failure: rational for preventive strategies and comprehensive disease management. Am Heart J.1997,133(6):703-712.
[73]Massie BM, Shah NB. The heart failure epidemic:magnitude of the problem and potential mitigating approaches. Curr Opin Cardiol,1996,11(3):221-226.
[74]Godar S, Horejsi V, Weidle UH, Binder BR, Hansmann C, Stockinger H.M6P/
IGFII-receptor complexes urokinase receptor and plasminogen for activation of
transforming growth factor-β1.Eur J Immunol.1999.29(3):1004-1013.
[75]Lee SD, Chu CH, Huang EJ, Lu MC, Liu JY, Liu CJ, Hsu HH, Lin JA, Kuo WW, Huang CY.Roles of insulin-like growth factor II in cardiomyoblast apoptosis and in hypertensive rat heart with abdominal aorta ligation. Am J Physiol Endocrinol Metab, 2006,291(2):E306-314.
[76]Chu CH, Tzang BS, Chen LM, Liu CJ, Tsai FJ, Tsai CH, Lin JA, Kuo WW, Bau DT, Yao CH, Huang CY.Activation of IGF2R induces Mitochondrial-dependent Apoptosis through Gaq and Downstream Calcineurin Signaling in Myocardial Cells.Endocrinology.2009,150 (6):2723-31.
[77]Chu CH, Tzang BS, Chen LM, Kuo CH, Cheng YC, Chen LY, Tsai FJ, Tsai CH, Kuo WW, Huang CY.IGF-II/mannose-6-phosphate receptor signaling induced cell hypertrophy and atrial natriuretic peptide/BNP expression via Gaq interaction and protein kinase C-a/CaMKII activation in H9c2 cardiomyoblast cells.Endocrinology, 2008,197(2):381-390.
[78].Dzau VJ, Brau-Dullaeus RC, Sedding DG. Vascular proliferation and atherosclerosis:new perspectives and therapeutic strategies. Nature Med.2002, 8(11):1249-1256.
[79]Zaina S, Pettersson L, Ahren B, Branen L, Hassan AB, Lindholm M, Mattsson R, Thyberg J, Nilsson J.Insulin-like growth factor II plays a central role in atherosclerosis in a mouse model. J Biol Chem.2002,277(6):4505-4511.
[80]Rogler CE, Yang D, Rossetti L, Donohoe J, Alt E, Chang CJ, Rosenfeld R, Neely K, Hintz R. Altered body composition and increased frequency of diverse malignancies in insulin-like growth factor-II transgenic mice. J Biol Chem.1994,269(19): 13779-13784.
[81]Da Costa TH, Williamson DH, Ward A, Bates P, Fisher R, Richardson L, Graham CF. High plasma insulin-like growth factor-II and low lipid content in transgenic mice: measurement of lipid metabolism. J Endocrinol.1994,143(3):433-439.
[82]Zaina S, Pettersson L, Ahren B, Branen L, Hassan AB, Lindholm M, Mattsson R, Thyberg J, Nilsson J. Insulin-like growth factor Ⅱ plays a central role in atherosclerosis in a mouse model. J Biol Chem 2002,277(6):4505-4511.
[83]Devedjian JC, George M, Casellas A, Pujol A, Visa J, Pelegrin M, Gros L, Bosch F. Transgenic mice overexpressing insulin-like growth factor-II in beta cells develop type2 diabetes. J Clin Invest 2000,105(6):731-740.
[84]Gibson JM, Westwood M, Young RJ, White A. Reduced insulin-like growth factor binding protein-1 (IGFBP-1) levels correlate with increased cardiovascular risk in non-insulin dependent diabetes mellitus (NIDDM). J Clin Endocrinol Metab 1996, 81(2):860-863.
[85]Libby P, Aikawa M. Stabilization of the atherosclerotic plaques:new mechanisms and clinical targets. Nat Med,2002,8(11):1257-1262.
[86]Mallat Z, Tedgui A. The role of transforming growth factor beta in atherosclerosis: novel insights and future perspectives.Curr Opin Lipidol.2002,13(5):523-529.
[87]Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, Barry M, Shostak I, Sawchuk T, Holmes CF, Gauldie J, Bleackley RC.Mannose 6-phosphate/insulin-like growth factor Ⅱ receptor is a death receptor for granzyme B during cytotoxic T cell-induced apoptosis.Cell.2000,103(3):491-500.
[88]Smith JD, Trogan E, Ginsberg M, Grigaux C, Tian J, Miyata M. Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. Proc Natl Acad Sci U S A.1995,92(18):8264-8268.
[89]Ikari Y, McManus BM, Kenyon J, Schwartz SM.Neonatal intima formation in the human coronary artery.Arterioscler Thromb Vasc Biol.1999,19(9):2036-40.
[90]Schwartz SM. The intima: A new soil.Circ Res.1999,85(10):877-9.
[91]Weninger WJ, Muller GB, Reiter C, Meng S, Rabl SU. Intimal hyperplasia of the infant parasellar carotid artery: a potential developmental factor in atherosclerosis and SIDS.Circ Res.1999,85(10):970-5.